Qurient partners with TB Alliance TB Alliance to develop telacebec

2023-02-06

临床结果临床2期孤儿药引进/卖出快速通道

Qurient partners with TB Alliance to develop telacebec

Preview

来源: Pharmaceutical Technology

Telacebec will be developed to treat tuberculosis and few non-tuberculosis mycobacteria infections. Credit: Department of Pathology, Calicut Medical college / Wikimedia.

South Korean biotechnology company Qurient has entered a licence agreement with TB Alliance TB Alliance for the development and commercialisation of telacebec (Q203).

Under the deal, TB Alliance TB Alliance will have the exclusive global license to develop and market telacebec except in Russia, South Korea, and the Commonwealth of Independent States (CIS) countries.

The first-in-class orally available investigational drug, Telacebec blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex.

It will be developed to treat tuberculosis (TB) and other non-tuberculosis mycobacteria (NTM) infections.

In preclinical and clinical studies, the drug showed potent efficacy against drug-sensitive and drug-resistant TB.

It was successfully evaluated in Phase IIa early bactericidal activity (EBA) study for the treatment of TB.

In March 2020, the findings from the trial were published in The New England Journal of Medicine.

Qurient CEO Kiyean Nam said: “As telacebec’s unique mechanism of action of blocking energy metabolism of the Mycobacterium can address all types of TB, including drug-resistant TB, we expect telacebec to potentially become an essential component of drug combination regimens for the treatment of TB.

“We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide.

“Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need.”

The US Food and Drug Administration (FDA) has granted Fast Track Designation and Orphan Drug Designation to telacebec.

The drug was also found to be effective against buruli ulcer (Mycobacterium ulcerans), a chronic, necrotising disease that affects the skin and sometimes bone.

TB Alliance president and CEO Mel Spigelman said: “New drugs like telacebec are urgently needed in the fight against TB as well as certain NTM infections – compounds with potentially impactful novel mechanisms of action can have a significant benefit in combating the TB pandemic.

“We look forward to advancing this new compound as part of combination regimens that could yield a short, simple, safe, and highly effective cure for all forms of TB.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构